You have full access to this article via your institution. To demonstrate the power of PCR–mediated recombination and provide an example of the general utility of the method, we constructed ...
This is best exemplified by chimeric antigen receptor (CAR) T-cells. Since first being tested in a patient nearly 15 years ago, six CAR T-cell products have been approved by the US Food and Drug ...
However, clinical studies of first-generation products targeting B-cell antigens demonstrated limited expansion and in vivo activity. Jensen et al 17 showed that outcomes of 15 CD19- or CD20-specific ...
Chimeric antigen receptor (CAR) T cell therapy is an approach that uses your own immune cells to fight cancer and has shown great promise in treating some types of blood cancers. Our researchers ...
T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to the induction of a powerful immune response. The ...
Researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients. This discovery has fueled new strategies that ...